SynapCell
PrivateLast Round
Grant
Jan 10, 2023
Total Funding Raised
$1.99M
Company Overview
SynapCell operates in Healthcare & Life Sciences and is based in France. Its latest recorded funding round was a Grant round in January 2023.
SynapCell is a biotechnology company that operates as a preclinical contract research organization specializing in translational EEG to evaluate drug candidates for central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SynapCell Comparables
Compare SynapCell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| E-Phy-Science | 86% | |
| Neuroservices-Alliance | 86% | |
| PsychoGenics Inc. | 86% |
For institutional investors. Book with your work email.
SynapCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 10, 2023 | ||||
| VC Round | Nov 5, 2010 | ||||
| Seed | Feb 1, 2009 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SynapCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Grenoble Angels | Seed, VC Round |
| Kreaxi | Seed, VC Round |
| Bpifrance | Grant |
| Expansinvest | Seed, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 29, 2024
Monthly visitors grew 450% MoM, reaching 1.1K.
- Jan 10, 2023
$1.29M grant received from Bpifrance.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 22, 2026
SynapCell plans to officially unveil its Cue(R)-based AI-powered offering at the Society for Neuroscience's annual meeting, Neuroscience 2026, in District of Columbia on Nov 17th '26; the offering combines quantitative electrophysiology with deep-learning AI to assess drug candidates across five therapeutic classes and support pharmaceutical research and development.
For institutional investors. Book with your work email.
SynapCell Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SynapCell's valuation, stock price, and market status.
Is SynapCell a public or private company?
SynapCell is a private company.
What is the current stock price of SynapCell?
SynapCell is a private company, so its shares have no public market price. Caplight tracks SynapCell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SynapCell worth (valuation)?
Valuation information for SynapCell is not publicly available.
Can I buy SynapCell stock?
SynapCell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SynapCell's last funding round?
SynapCell's most recent funding round was Grant on January 10, 2023.
Who are the main investors in SynapCell?
Key investors in SynapCell include Kreaxi.
Will SynapCell IPO soon?
No public IPO plans have been announced for SynapCell.
How can I track SynapCell secondary market activity?
Caplight tracks bids, offers, and trades in SynapCell's shares on secondary markets.